Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 215

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Open access
Cascone, Tina, Leung, Cheuk H., Weissferdt, Annikka, Pataer, Apar, Carter, Brett W., Godoy, Myrna C. B., Feldman, Hope, William, William N., Xi, Yuanxin, Basu, Sreyashi, Sun, Jing Jing, Yadav, Shalini S., Rojas Alvarez, Frank R., Lee, Younghee, Mishra, Aditya K., Chen, Lili, Pradhan, Monika, Guo, Haiping, Sinjab, Ansam, Zhou, Nicolas, Negrao, Marcelo V., Le, Xiuning, Gay, Carl M., Tsao, Anne S., Byers, Lauren Averett, Altan, Mehmet, Glisson, Bonnie S., Fossella, Frank V., Elamin, Yasir Y., Blumenschein, George, Zhang, Jianjun, Skoulidis, Ferdinandos, Wu, Jia, Mehran, Reza J., Rice, David C., Walsh, Garrett L., Hofstetter, Wayne L., Rajaram, Ravi, Antonoff, Mara B., Fujimoto, Junya, Solis, Luisa M., Parra, Edwin R., Haymaker, Cara, Wistuba, Ignacio I., Swisher, Stephen G., Vaporciyan, Ara A., Lin, Heather Y., Wang, Jing, Gibbons, Don L., Jack Lee, J., Ajami, Nadim J., Wargo, Jennifer A., Allison, James P., Sharma, Padmanee, Kadara, Humam, Heymach, John V., Sepesi, Boris · 2023 · Nature Medicine

Abstract

Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell lung cancer (NSCLC). The impact of adding ipilimumab to neoadjuvant Nivo+CT is unknown. Here we report the results and correlates of two arms of the phase 2 platform NEOSTAR trial testing neoadjuvant Nivo+CT and Ipi+Nivo+CT with major pathologic response (MPR) as the primary endpoint. MPR rates were 32.1% (7/22, 80% confidence interval (CI) 18.7–43.1%) in the Nivo+CT arm and 50% (11/22, 80% CI 34.6–61.1%) in the Ipi+Nivo+CT arm; the primary endpoint was met in both arms. In patients without known tumor EGFR/ALK alterations, MPR rates were 41.2% (7/17) and 62.5% (10/16) in the Nivo+CT and Ipi+Nivo+CT groups, respectively. No new safety signals were observed in either arm. Single-cell sequencing and multi-platform immune profiling (exploratory endpoints) underscored immune cell populations and phenotypes, including effector memory CD8+ T, B and myeloid cells and markers of tertiary lymphoid structures, that were preferentially increased in the Ipi+Nivo+CT cohort. Baseline fecal microbiota in patients with MPR were enriched with beneficial taxa, such as Akkermansia, and displayed reduced abundance of pro-inflammatory and pathogenic microbes. Neoadjuvant Ipi+Nivo+CT enhances pathologic responses and warrants further study in operable NSCLC. (ClinicalTrials.gov registration: NCT03158129.)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-02189-0

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 215

Metadata

Authors
Cascone, T., Leung, C. H., Weissferdt, A., Pataer, A., Carter, B. W., Godoy, M. C. B., Feldman, H., William, W. N., Xi, Y., Basu, S., Sun, J. J., Yadav, S. S., Rojas Alvarez, F. R., Lee, Y., Mishra, A. K., Chen, L., Pradhan, M., Guo, H., Sinjab, A., Zhou, N., Negrao, M. V., Le, X., Gay, C. M., Tsao, A. S., Byers, L. A., Altan, M., Glisson, B. S., Fossella, F. V., Elamin, Y. Y., Blumenschein, G., Zhang, J., Skoulidis, F., Wu, J., Mehran, R. J., Rice, D. C., Walsh, G. L., Hofstetter, W. L., Rajaram, R., Antonoff, M. B., Fujimoto, J., Solis, L. M., Parra, E. R., Haymaker, C., Wistuba, I. I., Swisher, S. G., Vaporciyan, A. A., Lin, H. Y., Wang, J., Gibbons, D. L., Jack Lee, J., Ajami, N. J., Wargo, J. A., Allison, J. P., Sharma, P., Kadara, H., Heymach, J. V., & Sepesi, B.
Venue
Nature Medicine
Published
2023-03
Volume
29
Issue
3
Pages
593-604
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4327568983
Cited by
215
References
26
FWCI
22.26
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. https://app.cochat.ai/papers/10.1038/s41591-022-02189-0
The paper
Cascone, T., Leung, C. H., Weissferdt, A., Pataer, A., Carter, B. W., Godoy, M. C. B., Feldman, H., William, W. N., Xi, Y., Basu, S., Sun, J. J., Yadav, S. S., Rojas Alvarez, F. R., Lee, Y., Mishra, A. K., Chen, L., Pradhan, M., Guo, H., Sinjab, A., . . . Sepesi, B. (2023). Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nature Medicine. https://doi.org/10.1038/s41591-022-02189-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.